Search company, investor...

Predict your next investment

Angel Investor (Individual)

Investments

2

About Sujal Shah

Headquarters Location

Want to inform investors similar to Sujal Shah about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Sujal Shah News

Tvardi Therapeutics Appoints Sujal Shah to Board of Directors

Jan 28, 2021

January 28, 2021 04:00 PM Eastern Standard Time HOUSTON--( BUSINESS WIRE )-- Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Sujal Shah, Chief Executive Officer of CymaBay Therapeutics , to its Board of Directors. Mr. Shah brings two decades of experience as an operator and advisor in the biotechnology sector to the Tvardi Board. Since 2017, he has been President and Chief Executive Officer at CymaBay Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for patients with liver and other chronic diseases. Previously, he served as Chief Financial Officer of CymaBay, taking the company public in 2014. Prior to CymaBay, Mr. Shah was a healthcare investment banker for Citigroup as well as Credit Suisse, where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused on life sciences. “Tvardi is thrilled to have Sujal join our board,” stated Ronald DePinho, M.D., Tvardi’s Chairman of the Board of Directors. “His experience in navigating financial markets and investors as well as operating and scaling a biotech company are incredibly relevant as Tvardi grows and becomes successful.” Mr. Shah added, “Tvardi is at an exciting juncture in its brief history as it advances its STAT3 platform across multiple clinical indications including cancer and fibrosis. I look forward to working alongside the Board and management during this growth phase of the company.” Mr. Shah also serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. He received an M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University. About Tvardi Therapeutics, Inc. Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3. STAT3 is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that the company’s lead asset in cancer, TTI-101, is well tolerated and has clinical activity across a broad range of tumors including multiple durable responses. To learn more, visit www.tvardi.com .

Sujal Shah Investments

2 Investments

Sujal Shah has made 2 investments. Their latest investment was in Awaz as part of their Angel on January 1, 2023.

CBI Logo

Sujal Shah Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/11/2023

Angel

Awaz

Yes

Harsh Jain, Lalit Keshre, Radhika Apte, Sujal Shah, and Undisclosed Angel Investors

2

2/17/2016

Angel

Subscribe to see more

Subscribe to see more

10

Date

1/11/2023

2/17/2016

Round

Angel

Angel

Company

Awaz

Subscribe to see more

Amount

New?

Yes

Subscribe to see more

Co-Investors

Harsh Jain, Lalit Keshre, Radhika Apte, Sujal Shah, and Undisclosed Angel Investors

Sources

2

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.